Skip to Main Content

Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC

Conditions

Lung

Phase Pilot

What is the purpose of this trial?

New treatment strategies have been developed in lung cancer targeting the Epidermal Growth Factor Receptor (EGFR). Patients with an activating mutation in the EGFR have high responds rates to the treatment and should be treated with a EGFR inhibitor as first line of treatment. Some wild type patients do as well respond but selection of these patients is more difficult.

Erlotinib has been labeling with 11C and used as a new PET tracer. Accumulation of the tracer (11C-erlotinib) in tumors has showed promising results for selection of responders.

The investigators now want to conduct a larger clinical study to evaluate if accumulation of tracer on a pre-treatment 11C-erlotinib PET/CT can predict responds to erlotinib.

  • Trial with
    Yale Cancer Center
  • Start Date
    08/31/2015
  • End Date
    04/30/2018
Trial Image

For more information about this study, contact:

Mark Dias

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/22/2018
  • Study HIC
    #1407014359